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Abstract
Myelofibrosis is a rare hematopoietic stem cell neoplasm leading to marked bone marrow fibrosis and ineffective hematopoiesis. 
We report a case highlighting the potential role of 18F fluorodeoxyglucose (FDG) positron emission tomography/computed tomog-
raphy (PET/CT) for therapy monitoring. A 62-year-old man with myelofibrosis underwent FDG-PET/CT for evaluation of the extent 
of disease before and after allogeneic stem cell transplantation (SCT). PET after SCT demonstrated complete normalization of 
initially increased bone marrow tracer uptake, consistent with bone marrow biopsy showing complete remission. 18F-FDG-PET/CT 
may become a valuable diagnostic tool in myelofibrosis, enabling both sensitive initial staging and therapy monitoring.
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Primary myelofibrosis (PMF) and the clinically indistinguishable 
secondary forms of myelofibrosis (post-essential thrombocythemia 
and post-polycythemia vera myelofibrosis) are BCR-ABL1-negative 
hematopoietic stem cell neoplasms leading to marked bone marrow 
fibrosis and inefficient bone marrow blood formation [1, 2]. PMF 
is a rare disease with a reported incidence of 1.5 per 100,000 per 
year [3]. Patients with myelofibrosis may present with various symp-
toms including marked hepatosplenomegaly, severe anemia, 
thrombotic events, fatigue and night sweats. PMF is associated 
with reactive bone marrow fibrosis due to abnormal deposition of 
collagen and proliferation of hyperactive bone marrow fibroblasts, 
replacing normal myelopoiesis and causing cytopenias [2]. Pa-
tients with symptomatic forms of PMF have a median survival of 
less than 5 years [4]. The only curative treatment approach in PMF 
is currently allogeneic hematopoietic stem cell transplantation 
leading to 5-year survival rates between 51% and 61% [4]. Bone 
marrow fibrosis shows rapid regression after stem cell transplanta-
tion. An imaging-derived surrogate parameter for bone marrow 
fibrosis would be desirable not only for initial staging of the extent 
of disease, but also for therapy monitoring and potential adjustment 
of therapy, given that sampling errors on bone marrow biopsies are 
a frequently encountered problem since fibrosis may be an inho-
mogeneous process with variable distribution [2].
We herein present the case of a 62-year-old man with a history 
of JAK2-V617F-negative primary myelofibrosis who underwent 
whole-body 18F-fluorodeoxyglucose (FDG) positron emission to-
mography/computed tomography (PET/CT) for evaluation of the 
extent of disease 1 week before and 12 months after allogeneic 
stem cell transplantation (Figure 1). PMF had been diagnosed 
6 months before the first PET/CT, and he presented with anemia 
and thrombocytopenia. He received an allogeneic stem cell 
transplantation from a related donor without major complications. 
Complete histo-hematological remission was achieved at the time 
of the follow-up PET/CT. 
This report highlights the potential usefulness of 18F-FDG-PET/CT 
to visualize the extent and activity of bone marrow fibrosis in 
PMF, and — more importantly — to monitor normalization of 
tracer uptake after successful stem cell therapy. In recent years, 
PET/CT using tracers like 18F-FDG or 18F fluorodeoxythymidine 
(FLT) has been increasingly used as a morphofunctional imag-
ing modality for both initial evaluation and therapy monitoring 
in various hematologic malignancies including several types of 
lymphoma and leukemia [5–9]. 
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Apart from malignant diseases including lymphoma [5], 
increased bone marrow 18F-FDG uptake has been reported in 
a variety of benign conditions, e.g. after administration of granu-
locyte colony stimulating factor (G-CSF) or following erythropoi-
etin therapy, which may cause false-positive results [10,  11]. 
Hyperplastic bone marrow is usually advocated as the main 
mechanism to explain tracer uptake in these patients. In contrast, 
myelofibrosis is characterized by marked inflammation of the bone 
marrow compartment [12] and uptake is likely caused by active 
inflammatory cells. Although quantitative values for normal bone 
marrow uptake have been published [13] they are not used in 
clinical routine because Standardized Uptake Values (SUVs) may 
be incalculably influenced by a variety of technical and biologi-
cal factors [14]. Bone marrow FDG uptake has to be regarded 
as pathologic if there is non-homogeneous focal uptake [15], or 
a bone marrow metabolism pattern which is not to be expected 
in the patient’s age group like in the present patient who dem-
onstrated atypical bone marrow expansion into the tibial bones.
This is a case of primary myelofibrosis with marked pre- 
-therapeutic and absent post-therapeutic tracer uptake on 
18F-FDG-PET/CT.
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Figure 1. Whole-body maximum intensity projection (MIP) FDG-PET image before stem cell transplantation (A) demonstrating inhomogeneous 
tracer uptake in the bone marrow of the axial skeleton (SUVmax 3.5) and the long bones (arrows). Corresponding transversal PET (B) image 
showing marked bilateral tracer uptake in femoral bone marrow (arrows). Corresponding bone marrow biopsy microphotograph (C) demonstrating 
marked bone marrow fibrosis (Gomori’s silver impregnation, ×250). Whole-body MIP FDG-PET image after allogeneic stem cell transplantation (D) 
showing complete resolution of abnormal bone marrow uptake. Corresponding transversal PET (E) image demonstrating unremarkable femoral 
bone marrow tracer accumulation. Corresponding bone marrow biopsy microphotograph (F) showing hypoplastic bone marrow without residual 
fibrosis (Giemsa stain, ×250)
